BMS Report Results of Opdivo + Radiation in P-III CheckMate -498 Study in Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma Multiforme

Shots:

• The P-III CheckMate -498 study involves assessing of Opdivo (nivolumab) + radiation vs temozolomide + radiation in patients with newly diagnosed O6- MGMT-unmethylated GBM
• The P-III CheckMate -498 (NCT02617589) study demonstrated that it did not meet its 1EPs i.e, OS and is safe for solid tumors
• Opdivo is PD-1 immune checkpoint inhibitor and is approved as a monothx. as well as combination therapy with Yervoy in the US & EU, currently evaluated in P-III CheckMate -548 (NCT02667587) study assessing Opdivo with SOC, radiation & temozolomide

Click here to read full press release/ article | Ref: BMS | Image: Dawson Design